Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Cisplatin is administered intravenously as short-term infusion in normal saline for treatment of solid and haematological malignancies. It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, [9] and germ cell tumors.
It takes 7 days of treatment to reach 90-95% of the steady-state serum concentration. [25] Anastrozole distributes completely around the body and only 40% of the drug is bound to plasma proteins. The elimination of anastrozole is slow and the elimination half-life is 40–50 hours.
Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation. [ 33 ] Cosibelimab (Unloxcyt) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by Dana Farber, and was approved in the United States in December 2024 for cutaneous squamous cell carcinoma .
Cisplatin was the first to be developed. [9] Cisplatin is particularly effective against testicular cancer; the cure rate was improved from 10% to 85%. [10] Similarly, the addition of cisplatin to adjuvant chemotherapy led to a marked increase in disease-free survival rates for patients with medulloblastoma - again, up to around 85%.
Gemcitabine, sold under the brand name Gemzar, among others, [1] is a chemotherapy medication used to treat cancers. [3] It is used to treat testicular cancer, [4] breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. [3] [5] It is administered by intravenous infusion. [3]
Ovarian stimulation with the aromatase inhibitor letrozole has been proposed for ovulation induction in order to treat unexplained female infertility. In a multi-center study funded by the National Institute of Child Health and Development, ovarian stimulation with letrozole resulted in a significantly lower frequency of multiple gestation (i.e., twins or triplets) but also a lower frequency ...
Side effects of thalidomide-induced peripheral neuropathy include sensory symptoms, possible motor impairment, and gastrointestinal and cardiovascular autonomic manifestations. The symptoms of immunomodulatory drugs may dictate whether treatment is continued or discontinued, and they can last long-term after chemotherapy completion. [3]